AMTM
Amentum Holdings, Inc.
AMTM offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CAT
Caterpillar Inc.
CAT has the edge over AMTM overall, supported by stronger modeled upside and stronger fundamentals.
AMTM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
AMTM's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMTM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.6x | $22.15 | — |
| Cheap | 26x | $21.30 | -3.8% |
| Current | 27x | $22.15 | — |
| Fair | 39x | $32.14 | +45% |
| Expensive | 108x | $89.29 | +303% |
Historical ranges are pointers, not guarantees.
AMTM has the edge over CAT in the historical PE scenario, which offers more potential upside but is not a forecast.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
AMTM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect AMTM's earnings to grow and its profitability to improve, with its revenue holding steady.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
CAT has the edge over AMTM on the outlook, with more favorable revenue expectations.
AMTM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.58 | +211% |
| Q2 2026 | $0.83 | +$3.68 |
| Q1 2026 | $0.60 | +$3.66 |
| Q4 2025 | $0.40 | +$2.76 |
| Q3 2025 | $0.27 | +$1.96 |
| Q2 2025 | -$2.85 | -271% |
| Q1 2025 | -$3.06 | -280% |
| Q4 2024 | -$2.36 | -298% |
| Q3 2024 | -$1.69 | -349% |
AMTM has the edge over CAT on earnings, with more consistent year-over-year improvement.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT earned $25.48 per share over the past year, up 31% from the year before.
AMTM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.5B | -2% |
| Q1 2026 | $3.5B | -0.4% |
| Q4 2025 | $3.2B | -5.2% |
| Q3 2025 | $3.9B | -7.5% |
| Q2 2025 | $3.6B | +66% |
| Q1 2025 | $3.5B | +145% |
| Q4 2024 | $3.4B | +151% |
| Q3 2024 | $4.2B | +189% |
AMTM's revenue fell from its 2024 peak and has held roughly level since: $3.5B last quarter, down 2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 4.9% | +2 points |
| Q1 2026 | 4.3% | +1.2 points |
| Q4 2025 | 4.3% | +0.4 points |
| Q3 2025 | 3.4% | +2.8 points |
| Q2 2025 | 2.9% | -1.3 points |
| Q1 2025 | 3.1% | -3.2 points |
| Q4 2024 | 3.9% | -2.6 points |
| Q3 2024 | 0.6% | -6 points |
AMTM's operating margin was 4.9% last quarter, up 2 points from the same quarter a year ago.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT's revenue has grown year over year for five quarters in a row: $20.7B last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over AMTM on profitability, with a higher operating margin.
AMTM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $135M | +35% |
| Q1 2026 | $220M | +315% |
| Q4 2025 | -$142M | -239% |
| Q3 2025 | $261M | +$378.2M |
| Q2 2025 | $100M | -58% |
| Q1 2025 | $53M | +2550% |
| Q4 2024 | $102M | +$187M |
| Q3 2024 | -$117.2M | -218% |
AMTM has the edge over CAT on cash flow, with more consistent year-over-year improvement.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT generated $11.3B in free cash flow over the past year, up 26% from the year before.
AMTM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +0.8% | +2M shares |
| 3 years | +0.7% | +1.7M shares |
AMTM has 245M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over AMTM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
AMTM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 3.3x | Elevated |
| Q1 2026 | 3.5x | Elevated |
| Q4 2025 | 3.8x | Elevated |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 4.4x | High |
| Q1 2025 | 5.4x | High |
| Q4 2024 | 6.6x | High |
| Q3 2024 | 9.4x | High |
AMTM's net debt is about 3.3 years of its operating earnings (EBITDA), down from 4.4 years a year ago.
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has the edge over AMTM on leverage, with a lower net debt burden relative to earnings.
AMTM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.2 | Neutral |
| Stochastic | 54.9 | Neutral |
AMTM's weekly RSI is 51 (neutral) and its Stochastic is 55 (neutral).
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
AMTM PE vs Industrials Sector
| Metric | AMTM | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 24x | 11% above |
| PE % | 26 | 32 | 6 pts below |
AMTM is trading at 27x earnings, a 11% premium to the Industrials sector's median of 24x.
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT has the edge over AMTM on valuation relative to its sector.
AMTM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.4 | 8.6% above |
| 20 week MA | $20.9 | 6% above |
| 50 week MA | $25.2 | 12% below |
| 100 week MA | $23.7 | 6.5% below |
AMTM has stronger trend alignment. AMTM is above 2 of 4 weekly averages versus CAT above 2 of 5.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
AMTM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $25.7 | $20.5 | -20% |
| 2025 | $20.5 | $29.7 | +45% |
| 2026 YTD | $29.7 | $22.2 | -25% |
AMTM has finished lower in one of the last two years. It's down 25% so far in 2026.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has the edge over AMTM on returns for 2026, with the stronger performance.